Are the Electronic and Paper Questionnaires Equivalent in Assessing Patients with Overactive Bladder?

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Overactive Bladder

Patient-targeted websites on overactive bladder: What are our patients reading?

Neurourol Urodyn.

Clancy AA, Hickling D, Didomizio L, Sanaee M, Shehata F, Zee R, Khalil H

doi: 10.1002/nau.23359.

Overactive Bladder

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Lupus.

Pereira E Silva R, Romão VC, Neves M, Garcia R, Oliveira S, Brites J, Ramos FO, Canhão H, Palma Dos Reis J, Pereira da Silva JA, Lopes T

doi: 10.1177/0961203318811605.

Overactive Bladder

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Patient.

Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N

doi: 10.1007/s40271-017-0262-8.

Overactive Bladder

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Neurourol Urodyn.

Niederhauser T, Gafner ES, Cantieni T, Grämiger M, Haeberlin A, Obrist D, Burkhard F, Clavica F

doi: 10.1002/nau.23357.

Overactive Bladder

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Eur Urol.

Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E

doi: 10.1016/j.eururo.2019.07.010.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive Bladder

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Int Urogynecol J.

Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR

doi: 10.1007/s00192-017-3377-5.

Overactive BladderUrinary Incontinence

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Int Urogynecol J.

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, Arumi D, Mangan E, Ntanios F

doi: 10.1007/s00192-018-3640-4.

Related content

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Patient-targeted websites on overactive bladder: What are our patients reading?

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?